PharmaFocus Today – Page 91 – media

744 million! Medical equipment dark horse completes Series C financing again

According to the Medicine Intelligence Data Investment Pattern Database, Precision Neuroscience (hereinafter referred to as Precision) recently announced the completion of a new round of $102 million (contract 740 million RMB) Series C financing, bringing its total capital to $155 million. Investors participating in this round of financing include General Equity Holdings, B Capital, Duquesne Family Office of Stanley F. Druckenmiller, and Steadview Capital. This round of financing will be used to expand Precision’s team, advance clinical research work, and refine future versions of its AI driven brain implants. These implants are designed to enable severely paralyzed users to operate digital devices such as computers and smartphones solely through thinking. In addition, according to the Medicine Intelligence Data Investment Pattern Database, Precision also completed a Series C financing on November 6th this year, with a financing scale of 93 million US dollars (contract 679 million RMB). Advanced Brain Computer Interface ...
- Source: drugdu
- 443
- December 28, 2024
Bi Jingquan won the DIA Lifetime Achievement Award, and he opened the chapter of China’s innovative drugs

On December 19, in Washington, the United States, the International Drug Information Association (DIA) awarded Bi Jingquan the DIA Lifetime Achievement Award to thank him for his long-term outstanding leadership and extraordinary courage in promoting drug innovation and international cooperation. The chairman of the China Center for International Economic Exchanges (CCIEE) and former director of the China Food and Drug Administration was once evaluated by the industry as: the best director of the Food and Drug Administration in many years, and is also regarded by many as one of the key figures in promoting the development of China’s innovative drug industry. DIA, which awarded Bi Jingquan this time, is a global, interdisciplinary international academic platform with a high reputation in the field of global pharmaceutical research and development. In 2017, when the Chinese drug regulatory authorities sought to join the International Council for Harmonization of Technical Requirements for Pharmaceuticals for ...
- Source: drugdu
- 286
- December 27, 2024
The first cell impermeable membrane covered stent has been approved by the FDA for market launch

Recently, Merit Medical announced that its non permeable membrane covered stent, Wrapsody, has been approved by the FDA for sale. This is the first product approved by the FDA for the treatment of vascular stenosis or thrombosis in hemodialysis patients. It is reported that Merit Medical will start commercialization in the United States next year.The first heavyweight product has been launched Founded in 1987, Merit Medical is a leading medical device manufacturing enterprise that produces instruments used in cardiac and radiological interventional surgeries. The product line of Merit Medical Company includes interventional filling devices and their accessories, diagnostic and therapeutic catheters and guide wires, disposable pressure monitoring equipment, contrast agent management systems, non vascular stents, thrombolytic catheters, syringes and needles, etc. The company is committed to meeting the needs of global cardiology and radiology experts through product development and high-quality production. Hemodialysis is currently the most widely used blood purification ...
- Source: drugdu
- 163
- December 27, 2024
Jiangsu ProteLight’s antimicrobial peptide product Peceleganan has applied for listing, and CTTQ Pharma has obtained exclusive cooperation rights in China

On December 24, the official website of the Drug Evaluation Center (CDE) of the State Food and Drug Administration announced that the marketing application of Pratt&Lyle’s Class 1 new drug Peceleganan Spray was accepted. In January 2023, CTTQ Pharma signed an exclusive commercial cooperation agreement with Pulei Pharmaceutical regarding the antimicrobial peptide product Peceleganan for the treatment of secondary wound infections in China. Peceleganan (PL-5) spray is a new polypeptide broad-spectrum anti infective drug, which belongs to non antibiotic anti infective drugs and has a unique bactericidal mechanism. According to the pipeline information on the official website of ProteLight Pharma, the fastest indication for the research process of this product is secondary wound infection. Secondary wound infection refers to open wound infection caused by various bacteria, including diabetes foot, bedsore, burn, etc. With the use of antibiotics, the proportion of drug-resistant bacteria is increasing, leading to the serious problem of ...
- Source: drugdu
- 247
- December 27, 2024
In 2023, both revenue and profit will decrease, and Taide Pharmaceutical will once again rush to the Hong Kong stock market for listing

In November, the weight reducing version of semaglutide, also known as “Novo Nordisk”, was officially launched in China. Simeglutide belongs to the GLP-1 (glucagon like peptide-1, a naturally occurring peptide hormone) receptor agonist class of peptide drugs, and Ted Pharmaceutical (Zhejiang) Co., Ltd. (hereinafter referred to as Ted Pharmaceutical) is a company in the related field. After its expiration in May 2024, the company has recently submitted another application to rush for listing on the Hong Kong stock market. According to the prospectus, Ted Pharmaceuticals claims to be the world’s third-largest peptide focused CRDMO (Contract Research, Development, and Production Organization), providing discovery, research, development, and manufacturing services in the pharmaceutical and/or biotechnology industry on a contractual basis. However, the performance of Ted Pharmaceuticals, which is currently in a hot spot, is not satisfactory. In 2023, the company experienced a decline in both revenue and profit. The reporter from the Daily ...
- Source: drugdu
- 146
- December 27, 2024
The original new drug manufacturing base project of Microchip has officially started construction

On the morning of December 24th, the “Pengzhou City Promotion of ‘Establishing a Full Garden’ Action Conference and Pengzhou Microchip Original New Drug Manufacturing Base Project Commencement Ceremony” was successfully held at Tianfu Traditional Chinese Medicine City in Pengzhou Economic Development Zone. It is reported that Shenzhen Weixin Biotechnology Co., Ltd., as the first enterprise to pass the Shanghai Stock Exchange’s Science and Technology Innovation Board and the first original new drug enterprise to list on the board, has been deeply engaged in the research and development of innovative drugs for more than 20 years. It has won the first prize of the National Science and Technology Progress Award and the China Patent Gold Award, ranking 18th on the list of China’s top 100 pharmaceutical innovation enterprises. It is committed to developing original new drugs with great clinical value, achieving multiple breakthroughs in major disease fields, and giving birth to ...
- Source: drugdu
- 286
- December 27, 2024
The first Chinese-led lung cancer targeted drug has been approved by the FDA

Before 2016, if the revenue ratio was used as an identification indicator, all pharmaceutical companies listed on the A-share market were “generic drug” companies. Until the emergence of Beida Pharmaceuticals. Beida Pharmaceuticals was established in 2003 and has long focused on the development of small molecule innovative drugs in the field of lung cancer. Its drug Icotinib is my country’s first small molecule targeted anticancer drug with completely independent intellectual property rights, and it is also the first independent innovative drug with annual sales of more than 1 billion yuan. On November 7, 2016, Beida Pharmaceuticals was successfully listed on the Growth Enterprise Market, becoming the first pharmaceutical company in the A-share market whose main income comes entirely from innovative drugs, and is known as the “first innovative drug stock.” In December 2024, after experiencing the previous layoffs, Beida Pharmaceuticals ushered in another important milestone in its development history. On ...
- Source: drugdu
- 208
- December 27, 2024
fees are stipulated for the first time, and anti-aging is not mentioned

The number of stem cell clinical research projects in China ranks second in the world. In the China Clinical Trial Registry (ChiCTR), searching with “stem cells” as the keyword, as of September 2024, it can be retrieved that more than 100 medical institutions and 738 stem cell clinical research projects have been successfully registered in ChiCTR, and 38 stem cell clinical research projects have been successfully registered in ChiCTR in 2024. China’s stem cell clinical research has entered a period of vigorous development, including the Beijing-Tianjin-Hebei region represented by Beijing, the Yangtze River Delta region represented by Shanghai, the Pearl River Delta region represented by Shenzhen, the free trade pilot zone represented by Hunan, and the “medical special zone” represented by the Hainan Boao Lecheng International Medical Tourism Pilot Zone, etc. These regional clusters are making their own efforts to actively seize the commanding heights of the biomedical industry. The ...
- Source: drugdu
- 300
- December 27, 2024
It’s 2024, why is there still no medicine for “dysmenorrhea”?

To this day, there is still no medicine for dysmenorrhea. Although in social concepts, dysmenorrhea is regarded as a common pain for women. Many women choose to endure or take painkillers to get through menstrual pain, and few people go to the doctor for this. However, dysmenorrhea is not always harmless, and this tolerance may hide great hidden dangers. Dysmenorrhea, especially severe dysmenorrhea, is likely to be a disease-endometriosis. Endometriosis is far more than just dysmenorrhea. It can not only invade surrounding tissues and other organs, causing complex symptoms, but also easily recur after treatment, and can only be relieved after menopause, bringing endless pain and torture to patients, and even called “immortal cancer”. Behind this, there are certainly many reasons. For example, wrong and rigid social concepts; for example, both patients and medical staff lack the awareness of early diagnosis and early treatment of endometriosis; most importantly, due to ...
- Source: drugdu
- 277
- December 27, 2024
CSPC AI exploded

CSPC Pharmaceutical Group has reached a blockbuster BD again. Recently, CSPC Pharmaceutical announced that it has reached a BD agreement with BeiGene on the group’s new methionine adenosyltransferase 2A (MAT2A) inhibitor, SYH2039, and will grant BeiGene the rights to develop and commercialize the pipeline globally. The BD amount this time is also very impressive: CSPC Pharmaceutical Group will receive a total of US$150 million in advance payments, and is entitled to receive up to US$135 million in potential development milestone payments and up to US$1.55 billion in potential sales milestone payments, as well as tiered sales commissions calculated based on the annual net sales of the product. It is worth mentioning that the compound was screened by CSPC Pharmaceutical through AI technology. Previously, CSPC Pharmaceutical also BD a preclinical pipeline screened by AI technology to AstraZeneca at a high price. CSPC Pharmaceutical AI exploded. ▍Why CSPC Pharmaceutical? The molecule of ...
- Source: drugdu
- 377
- December 27, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.